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Introduction
The CDC-RTI Diabetes Cost-Effectiveness Model was designed to simulate the development and progression of type 2 diabetes to assess the costeffectiveness of various prevention and treatment interventions. To provide results useful for guiding public health policy, the model should accurately represent the experience of the diabetes population. Model validation helps ensure the accuracy of the model and is an important step in the construction of any disease model. The American Diabetes Association (ADA) Consensus Panel 1 described the importance of validating diabetes models and provided steps to guide researchers in the validation process.
The model has undergone informal and formal validation exercises, but these exercises have not been presented systematically. In addition, the model has been revised over the years to incorporate new data, revised parameters, and new functions. For example, we have incorporated the United Kingdom Prospective Diabetes Study (UKPDS) risk engines for coronary heart disease (CHD) and stroke in place of Framingham equations, and we have added a module for prediabetes (defined here as persons with impaired fasting glucose or impaired glucose tolerance who are at high risk of developing diabetes). Recently, we updated the model to incorporate recent data on costs, diabetes incidence, and mortality. Therefore, the objective of this analysis is to present the results of the validation of the CDC-RTI Diabetes CostEffectiveness Model, Version 6.2.
Methods

The CDC-RTI Diabetes Cost-Effectiveness Model
The CDC-RTI Diabetes Cost-Effectiveness Model is a Markov simulation model of disease progression and cost-effectiveness for type 2 diabetes. To reflect the chronic nature of diabetes, the model follows patients from diagnosis to either death or age 95 years. The model simulates development of diabetesrelated complications on three microvascular disease paths (nephropathy, neuropathy, and retinopathy) and two macrovascular disease paths (CHD and stroke). The model also contains modules for diabetes screening and prediabetes. Model outcomes include disease complications, deaths, costs, and quality-adjusted life years (QALYs). In the model, progression between disease states is governed by transition probabilities that depend on risk factors-including glycemic level (measured by HbA1c levels), blood pressure, cholesterol, and smoking status-and duration of diabetes. Interventions affect the transition probabilities and resulting complications. For example, tight glycemic control lowers HbA1c, slowing progression on the microvascular complication paths. With slower progression, fewer microvascular complications occur, deaths are delayed, QALYs increase, and the costs of complications are reduced. The model has been used to estimate the cost-effectiveness of treatment interventions for patients with diagnosed diabetes, 2 evaluate optimal resource allocation across interventions, 3 assess whether screening for diabetes is cost-effective, 4 show that lifestyle modification is cost-effective in delaying or preventing diabetes among persons with prediabetes, 5 and estimate the cost-effectiveness of screening for prediabetes. 6 Additional details about the model can be found in the study of the cost-effectiveness of treatments for patients with diagnosed diabetes 2 or in the technical report accompanying the model (available upon request).
Validation Procedures
We follow general validation procedures outlined by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force 7 and by the ADA Consensus Panel1 on computer modeling in diabetes as well as methods used in validation studies of the Archimedes Diabetes Model 8 and the CORE Diabetes Model. 9 For the validation, we input baseline model parameters from studies that were used to create the model (internal validation) and those that were found from a review of the literature (external validation). We then ran the model and compared the overall outcomes in the model to those reported by the validation studies. We performed internal and external validation using 47 outcomes/complications from a mix of 24 published randomized trials and cohort studies, and one disease progression and cost-effectiveness model. For internal validation, we included only those studies that were used to construct the model; for external validation, we examined the existing literature to find studies that were not used to design the model parameters.
For external validation, we first examined the studies used to validate the Archimedes Diabetes Model 8 and the CORE Diabetes Model. 9 For each of these studies, we included only those studies where the study population was appropriate to use in the CDC-RTI Diabetes Cost-Effectiveness Model, namely the population with type 2 diabetes. To supplement the studies used in the validation of the Archimedes and CORE Models, we performed a PubMed search of diabetes and each of the model complications (microalbuminuria, macroalbuminuria, end-stage renal disease [ESRD] , neuropathy, lower extremity amputation [LEA] , blindness, myocardial infarction [MI], angina, stroke, all-cause mortality, and progression from prediabetes to diabetes). For each of the diabetes complications, we included only studies that had outcomes for persons with type 2 diabetes. For prediabetes, we included only studies that measured the incidence of diabetes within a population with impaired glucose tolerance (IGT).
We performed internal and external validation by comparing complications and outcomes from the model to those observed in each study included in the validation exercises. For each validation exercise, we created a cohort with descriptive statistics similar to those of the population in the comparison study. Based on the existing structure of our model, we used the following variables to create the cohorts: age, sex, race/ethnicity, blood pressure, total cholesterol, and smoking status. After running the model for the simulated cohort, we compared the model outcomes/ complications to the outcomes/complications described in the comparison study. Some of the comparisons included conventional glycemic control, while others involved intensive glycemic control. We assessed the goodness-of-fit for the model by plotting model results against the published results and then calculating R 2 values to measure how much of the actual variance our model can explain.
Results
Information on each study and the comparison between model outcomes/complications and validation study results are shown in Table 1 . The results in Table 1 show that, overall, the model accurately simulates the natural history of the diabetes population and predicts the progression from prediabetes to diabetes. For the majority of complications, the model results closely match the published results. Cumulative incidence of angina [31] 11.1% 4.0%
Cumulative incidence of stroke [32] 8.0% 1.4%
Calhoun et al. 24 (CARDS) Note: Numbers correlate to Outcome numbers from Table 1 . Event rates per 1,000 patient years were converted to incidence rates by multiplying the event rate by the number of years of follow-up.
The external validation (which focuses on studies that were not used in creating the model) had a regression slope of 0.991 and a high R 2 value of 0.969.
Note: Numbers correlate to Outcome numbers from Table 1 . Event rates per 1,000 patient years were converted to incidence rates by multiplying the event rate by the number of years of follow-up.
The results from the internal validation (only those studies used in creating the model) closely match the actual data-the regression line slope of 1.001 is close to 1.000, and the R 2 value is 0.992, which indicates that the model explains approximately 99 percent of the variance in the actual data.
Microvascular Complications
We assessed the model fit for three categories of microvascular complications: nephropathy, neuropathy, and retinopathy. The model accurately predicts these specific microvascular complications overall, with an R 2 value of 0.986. The model is similarly accurate for the three nephropathy complications (microalbuminuria, macroalbuminuria, and ESRD), with an R 2 value of 0.981. Because of the complicated nature of kidney disease, the model predicted the outcomes for the earlier stages (microalbuminuria) better than for the later stages (macroalbuminuria or ESRD). Few studies were available to validate the neuropathy and retinopathy complications, so, although the model fit the actual data well, we did not calculate an R 2 value for each of these specific complications.
For internal validation, we also analyzed how well the model matched the UKPDS results across each time period. We compared the UKPDS trial results with the model results for the incidence of peripheral neuropathy, microalbuminuria, and proteinuria (see Appendix Figures 1, 2, and 3 ). In general, the model fit the UKPDS results well over time, although the model fits the data better in earlier years and then slightly underestimates the rates of peripheral neuropathy, microalbuminuria, and proteinuria in later years.
Macrovascular Complications
We also assessed the model fit for macrovascular complications, which included CHD (angina and MI) and stroke. The model fit was better for CHD (R 2 = 0.982) than for stroke (0.800), although the worse fit for stroke was due primarily to several older studies used in the comparison. Overall, the model fit the macrovascular complications well, with an R 2 value of 0.958. For the macrovascular complications, we also examined how well the model results matched the UKPDS results over time. The model appears to model the incidence of MI and stroke well in the earlier years (see Appendix Figures  4 and 5) . However, in the later years, the model underestimated the incidence of MI and stroke.
Development of Diabetes from Prediabetes
We plotted the model results and the published results for the percentage of individuals with IGT against time in Figure 3 . We connected the model results with a line to indicate how the model predicted incidence of diabetes over time.
The specific points in the figure are based on the duration time reported in the results for each trial.
For that time, we plotted the published cumulative incidence of diabetes from the trial (diamonds) and the cumulative incidence predicted by the model (triangles). As expected, the model most closely matched the results from the Diabetes Prevention Program (DPP), which was used in constructing the model. Although the model does not perfectly match the published results, the model fit well (R 2 = 0.913), with the published results evenly distributed above and below the model prediction. 
Mortality
The model accurately predicts the total-cause mortality for the Japanese diabetes population in Sasaki et al. 29 and the American diabetes population in Gu, Cowie, and Harris. 28 Despite the difference in country, the model is within 10 percent of the published estimate for Japan. Note: Numbers correlate to Outcome numbers from Table 1 .
Discussion
As the ADA Consensus Panel indicated, validation is an essential part of designing any diabetes model. The process helps define the population for which the model is applicable and demonstrates the model's accuracy in representing actual diabetes progression. Although the model has been continuously validated throughout the model construction process, primarily by checking for programming errors and using internal validation, results of systematic validation have not been presented. This comprehensive validation process by the developers of the model shows that the model accurately simulates the development of diabetes and its complications.
The external validation also indicates that the model can accurately simulate the progression of diabetes for populations not used directly in model construction. This is particularly important because it demonstrates that the model can be applied to similar populations to estimate the cost-effectiveness of new interventions. However, our model is limited to the populations for which we have data, primarily people from clinical trials in the United States and the United Kingdom. The more a population differs from the one used to build the model, the less accurate the model will be in simulating that population.
We excluded several studies from the validation results because the study populations did not fit the model structure and were therefore not appropriate to use in the model. For example, the Parving et al. study, 35 Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, 36 and Irbesartan in Diabetic Nephropathy Trial (IDNT) 37, 38 only included populations with somewhat advanced kidney disease. Because our model primarily used UKPDS data, the model parameters are set to match a more heterogeneous group and not a population that exclusively has kidney disease. We also excluded the Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) study 39 because the study was relatively old and the population had very poor glycemic control. As diabetes care has improved, the rate of diabetes complications has decreased, so the data on which the model was built may not be applicable to the older WESDR study.
Overall, the internal validation shows that the model can accurately reproduce results from the studies used to create the model. The two exceptions are the results for MI and stroke over time. For MI and stroke, the model estimates incidence well for the first 9 years but then underestimates cumulative incidence in the later years. Although the model underestimates cumulative incidence, the model appears to be fairly accurate in the estimation of MI and stroke events per 1,000 patient years. This can be partly explained by the use of the UKPDS risk engine in the model, which calculates the probability of MI or stroke absent mortality from any other causes. However, our model includes multiple causes of death, which reduce life years and consequently lower the likelihood of a person having an MI or stroke during his/her lifetime. This may explain the lower incidence of MI or stroke in the later years, while the reduced life years explain how the model still estimates the number of events per 1,000 patient years well.
Stroke is the one notable complication where the model does not perform as accurately in external validation exercises. However, the rate of stroke seems to vary widely within the published results, so it would be difficult to match the results from each study. One reason for the variation may be secular improvements in stroke prevention, especially within the diabetes population. As stroke prevention has improved, the rate of strokes has decreased. Although the model has some trouble modeling the incidence of stroke, it does appear that the prediction is better for more recent studies than for older studies, as shown in Figure 4 . Figure 4 presents the rate of stroke by the final study year. We made similar graphs using the beginning study year and the middle study year (graphs not shown), but these changes did not affect the basic result.
In addition to stroke, the model is also not as accurate in predicting the progression from prediabetes to incident diabetes for the international studies included in the external validation exercises. However, as Table 1 and Figure 3 show, the published results for the incidence of diabetes vary considerably. For example, the cumulative incidence of diabetes was 9 percent with follow-up of 4 years in the Japan Diabetes Prevention Program, 33 55 percent with 3 years of follow-up from the Indian Diabetes Prevention Program, 32 and 42 percent with 3.3 years of follow-up in the Study to Prevent NIDDM (STOP-NIDDM). 34 Because of the wide variation in published results, it would be difficult to accurately predict the results for each individual country. The differences in diabetes incidence rates between countries may stem from differences in the definition of prediabetes across countries; differences in the eligibility requirements across studies; or countryspecific factors, such as the potential variation in typical care provided for the prediabetes population. The model was constructed to accurately predict the results for the DPP, which it does, and may be more appropriate for predicting the incidence of diabetes in an American population.
There are at least two options for improving the fit of the model for prediabetes. First, and most simply, we could use country-specific data to set the transition probability to diabetes every time we wish to study progression in a different country. This approach will capture country-specific effects on diabetes, but it will not reflect patient heterogeneity unless patientspecific data from that specific country are also available. Second, instead of using a single parameter to represent the transition probability, we could replace the parameter with a function that depends on a set of patient characteristics such as those used in the Framingham Offspring Study algorithm for estimating 8-year diabetes incidence. 40 Such an approach would incorporate patient heterogeneity, although it would not necessarily reflect countryspecific effects on incidence, and it may not fully reflect differences in patient populations within the United States. 41 
Conclusions
The CDC-RTI Diabetes Cost-Effectiveness Model's purpose is to assess the cost-effectiveness of various prevention and treatment interventions by simulating the development and progression of type 2 diabetes. However, the cost-effectiveness estimates are only useful if the simulation is an accurate representation of the true clinical course of diabetes. To ensure the accuracy of the model, an essential step in the development of any disease model is validation.
Our validation exercises show that the model accurately simulates the development and progression of diabetes. The validation results also indicate that the model can be effectively used to compare the cost-effectiveness of various diabetes prevention or treatment programs for the type 2 diabetes population. Although the model accurately simulates the incidence and progression of type 2 diabetes for most populations, it may not be as well suited for several other populations. The model may not be appropriate for diabetes populations where the entire population already has advanced stages of complications (e.g., the population with advanced kidney disease) or for populations with very poor glycemic control (e.g., the WESDR population). As the prediabetes results showed, the model also may not be as accurate for non-US populations, because medical treatment may differ geographically. In these cases, it may be possible to improve model accuracy by changing the model's default parameters while retaining the model's underlying structure. For example, when dealing with a known population of persons with advanced kidney disease, it may be possible to insert transition probabilities associated with this population. For persons with prediabetes in another country, it may be possible to use a countryspecific probability of developing diabetes.
As highlighted in the ISPOR disease modeling guidelines, models must be continuously updated as new information emerges. 7 As we update the model structure and inputs, we will continue to perform validation exercises to ensure that the model accurately simulates diabetes incidence and progression. Figures 1 through 3 compare the UKPDS trial results with the model results for the incidence of peripheral neuropathy, microalbuminuria, and proteinuria, respectively. In general, the model appears to fit the data well over time, although the model fits the data better in the earlier years. For peripheral neuropathy, the model appears to fit the data very well until 12 years after randomization, when the model appears to slightly underpredict the incidence of peripheral neuropathy. For microalbuminuria, the model appears to slightly overpredict incidence for the intensive glycemic control group; and for the conventional glycemic control group, the model slightly overpredicts during the earlier years and then underpredicts during the later years. Finally, for proteinuria, the model appears to predict the incidence very well for the intensive glycemic control group; and for the conventional glycemic control group, the model overpredicts slightly during the earlier years and underpredicts slightly during the later years. Overall, the model appears to do a good job approximating the UKPDS results over time. 
Macrovascular Complications
We also assessed the model fit for macrovascular complications, which included coronary heart disease (CHD) (angina and myocardial infarction [MI] ) and stroke. The model fit was better for CHD (R 2 = 0.982) than for stroke (0.800), although the low model fit for stroke was due primarily to several older studies. Overall, the model fit the macrovascular complications well, with an R 2 value of 0.958.
For the macrovascular complications, we also examined how well the model results matched the UKPDS results over time. As Figures 4 and 5 show, the model appears to accurately model the incidence of both MI and stroke well in the earlier years. However, in the later years, the model appears to underestimate the incidence of MI and stroke. This may be partially explained by the relatively lower number of participants remaining at the 15-year point-approximately 70 (of 1,096) in the conventional treatment group and 188 (of 2,632) in the intensive treatment group. RTI International is an independent, nonprofit research organization dedicated to improving the human condition by turning knowledge into practice. RTI offers innovative research and technical solutions to governments and businesses worldwide in the areas of health and pharmaceuticals, education and training, surveys and statistics, advanced technology, international development, economic and social policy, energy and the environment, and laboratory and chemistry services.
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